Pegcetacoplan Clinical Trials (2026): 27 Studies for Complement 3 Glomerulopathy (C3G) & C3G
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
27 Pegcetacoplan clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 16 indications (including Complement 3 Glomerulopathy (C3G) & C3G) and 3,295 total planned enrollment. 8 Phase 3 Pegcetacoplan trials and 9 Phase 2 are listed. 7 Pegcetacoplan clinical trials are actively recruiting at 71 U.S. sites across 24 states. Most recent activity: NCT05776472 (Aug 2029).
Where to Participate: All Pegcetacoplan Trial Sites in the U.S. (71 sites across 24 states)
Every actively recruiting Pegcetacoplantrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Associated Retina Consultants (01065) | Gilbert85297 | NCT07215390 | Map |
| AZ | Barnet Dulaney Perkins Eye Center (01018) | Mesa85206 | NCT07215390 | Map |
| AZ | Associated Retina Consultants - Phoenix | Phoenix85020 | NCT07215390 | Map |
| AZ | Retinal Research Institute, LLC (01021) | Phoenix85053 | NCT07215390 | Map |
| CA | California Retina Consultants (CRC) - Bakersfield Office | Bakersfield93309 | NCT07215390 | Map |
| CA | The Retina Partners - Encino | Encino07003 | NCT07215390 | Map |
| CA | Retina Consultants of Orange County - Fullerton Office | Fullerton93825 | NCT07215390 | Map |
| CA | Salehi Retina Institute, Inc dba Retina Associate or Southern California (01034) | Huntington Beach92647 | NCT07215390 | Map |
| CA | Salehi Retina Institute, Inc. Dba Retina Associates of Southern California (01034) | Huntington Beach92647 | NCT07215390 | Map |
| CA | California Retina Consultants (01054) | Oxnard93036 | NCT07215390 | Map |
| CA | Retina Consultants San Diego | Poway92064 | NCT07215390 | Map |
| CA | Orange County Retina Medical Group | Santa Ana92705 | NCT07215390 | Map |
| CA | Bay Area Retina Associates - Walnut Creek | Walnut Creek94598 | NCT07215390 | Map |
| CO | Colorado Retina Associates, PLLC | Lakewood80228 | NCT07215390 | Map |
| CO | Advanced Vision Research Institute | Longmont80503 | NCT07215390 | Map |
| CT | Connecticut Eye Consultants, PC (01074) | Danbury06810 | NCT07215390 | Map |
| FL | ClearVista Clinical Research, LLC (01096) | Bayonet Point34667 | NCT07215390 | Map |
| FL | Florida Retina Institute - Orlando (01053) | Orlando32806 | NCT07215390 | Map |
| FL | Florida Retina Institute (01053) | Orlando32806 | NCT07215390 | Map |
| FL | Retina Specialty Institute - Pensacola | Pensacola32503 | NCT07215390 | Map |
| FL | Eye Associates of Pinellas (01020) | Pinellas Park33782 | NCT07215390 | Map |
| FL | Retina Vitreous Associates of Florida (RVA) - Saint Petersburg | St. Petersburg33711 | NCT07215390 | Map |
| FL | Center for Retina and Macular Disease (01026) | Winter Haven33880 | NCT07215390 | Map |
| GA | Children's Hospital of Atlanta | Atlanta30329 | NCT04901936 | Map |
| GA | Southeast Retina Center | Augusta30909 | NCT07215390 | Map |
| IL | Illinois Retina Associates, S.C. - Oak Park (01061) | Oak Park60304 | NCT07215390 | Map |
| IN | Midwest Eye Institute (01066) | Carmel46032 | NCT07215390 | Map |
| IN | Advancing Research International. LLC (01090) | Indianapolis46214 | NCT07215390 | Map |
| IN | Retina Consultants P.C. | Indianapolis46214 | NCT07215390 | Map |
| LA | Retina Associates New Orleans - Jefferson Parish Location | Metairie70001 | NCT07215390 | Map |
| MD | The Retina Group of Washington (01089) | Chevy Chase29902 | NCT07215390 | Map |
| MD | Cumberland Valley Retina Consultants (CVRC) | Hagerstown21740 | NCT07215390 | Map |
| MS | Mississippi Retina Associates | Madison39110 | NCT07215390 | Map |
| NJ | Envision Ocular, LLC (01027) | Bloomfield07003 | NCT07215390 | Map |
| NJ | Mid Atlantic Retina (01039) | Cherry Hill08034 | NCT07215390 | Map |
| NJ | NJ Retina (01031) | Edison08820 | NCT07215390 | Map |
| NJ | NJ Retina (01030) | Toms River08755 | NCT07215390 | Map |
| NM | Vision Research Center Eye Associates of New Mexico (01023) | Albuquerque87109 | NCT07215390 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT04919629 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT07214298 | Map |
| NY | Long Island Vitreoretinal Consultants (01050) | Great Neck11021 | NCT07215390 | Map |
| NY | Long Island Vitreoretinal Consultants - Westbury | Long Island City11590 | NCT07215390 | Map |
| OH | Retina Assocaites of Cleveland, Inc (01048) | Cleveland44122 | NCT07215390 | Map |
| OR | Verum Research, LLC | Eugene97401 | NCT07215390 | Map |
| OR | EyeHealth Northwest | Portland97225 | NCT07215390 | Map |
| OR | EyeHealth Northwest (01006) | Portland97228 | NCT07215390 | Map |
| OR | Cascade Medical Research Institute, LLC (01070) | Springfield97477 | NCT07215390 | Map |
| PA | Mid Atlantic Retina - Philadelphia (01017) | Philadelphia19107 | NCT07215390 | Map |
| SC | Charleston Neuroscience Institute (01037) | Beaufort29902 | NCT07215390 | Map |
| SC | Retina Consultants of Carolina, PA (01073) | Greenville29605 | NCT07215390 | Map |
| SC | Charleston Neuroscience Institute LLC - Ladson | Ladson29456 | NCT07215390 | Map |
| SC | Charleston Neuroscience Institute, LLC - Mount Pleasant (01051) | Mt. Pleasant29464 | NCT07215390 | Map |
| SD | Ophthalmology Ltd. (01084) | Sioux Falls57108 | NCT07215390 | Map |
| TN | Tennessee Retina, PC (01063) | Nashville37203 | NCT07215390 | Map |
| TX | Retina Consultants of Texas - Abilene (01035) | Abilene79606 | NCT07215390 | Map |
| TX | Austin Retina Associates | Austin78705 | NCT07215390 | Map |
| TX | Retina Consultants of Texas - Bellaire (01067) | Bellaire77401 | NCT07215390 | Map |
| TX | Texas Retina Associates | Dallas75231 | NCT07215390 | Map |
| TX | Retina Consultants of Texas - Katy | Katy77494 | NCT07215390 | Map |
| TX | Valley Retina Institute- McAllen (01076) | McAllen78503 | NCT07215390 | Map |
| TX | Austin Retina Associates - Round Rock (01032) | Round Rock78681 | NCT07215390 | Map |
| TX | Retina Consultants of Texas - San Antonio Medical Center | San Antonio78240 | NCT07215390 | Map |
| TX | Austin Retina Associate (01046) | San Marcos78666 | NCT07215390 | Map |
| TX | Retina Consultants of Texas (01055) | Schertz78154 | NCT07215390 | Map |
| TX | Retina Center of Texas - Southlake | Southlake76092 | NCT07215390 | Map |
| TX | Retina Consultants of Texas - The Woodlands | The Woodlands73384 | NCT07215390 | Map |
| TX | Tyler Retina Consultants | Tyler75703 | NCT07215390 | Map |
| UT | Retina Associates of Utah (01052) | Salt Lake City84107 | NCT07215390 | Map |
| UT | Salt Lake Retina (01044) | West Jordan84088 | NCT07215390 | Map |
| VA | Piedmont Eye Center (01097) | Lynchburg24502 | NCT07215390 | Map |
| WI | University of Wisconsin Health - University Station Clinic | Madison53705 | NCT07215390 | Map |
Pegcetacoplan clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | not yet recruiting | approved for marketing | Total |
|---|---|---|---|---|---|---|---|
| P1 | 4 | 1 | 5 | ||||
| P1/P2 | 1 | 1 | 2 | ||||
| P2 | 3 | 1 | 4 | 1 | 9 | ||
| P3 | 1 | 1 | 6 | 8 | |||
| N/A | 1 | 1 | 1 | 3 |
Recruiting Pegcetacoplan clinical trials (7)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05776472 | COMPLETEA Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | — | Paroxysmal Nocturnal Hemoglobinuria | 200 | Jun 2023 |
| NCT04901936 | PNHA Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | P2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 12 | Feb 2021 |
| NCT07214298 | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | P1/P2 | Metastatic Pancreatic Ductal Adenocarcinoma | 35 | Feb 2026 |
| NCT07020832 | DGFA Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation | P3 | Delayed Graft Function | 320 | Feb 2026 |
| NCT04919629 | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | P2 | Fallopian Tube Carcinosarcoma | 60 | Apr 2023 |
| NCT07215390 | APL-2A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio | P2 | Geographic Atrophy Secondary to Age-related Macular Degeneration | 240 | Jun 2025 |
| NCT07495722 | SUCCESSSafely Quenching Complement in Stroke Survivors | P1 | Acute Ischemic Stroke | 20 | Oct 2026 |
Pegcetacoplan clinical trials by indication
C3G (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05809531 | VALE | P3 | active not recruiting | An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis |
| NCT04572854 | NOBLE | P2 | completed | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN |
| NCT05067127 | VALIANT | P3 | completed | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis |
| NCT04729062 | — | N/A | approved for marketing | C3G/Primary IC-MPGN EAP |
Geographic Atrophy Secondary to Age-related Macular Degeneration (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07215390 | APL-2 | P2 | recruiting | A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio |
| NCT07214740 | — | P3 | completed | Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe |
| NCT04770545 | GALE | P3 | completed | An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD |
Geographic Atrophy (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06161584 | — | N/A | active not recruiting | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration |
| NCT03777332 | — | P1 | completed | Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy |
| NCT02503332 | FILLY | P2 | completed | Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy |
Paroxysmal Nocturnal Hemoglobinuria (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05776472 | COMPLETE | N/A | recruiting | A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| NCT03500549 | PNH | P3 | completed | Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| NCT02588833 | PADDOCK | P1 | completed | Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects. |
Paroxysmal Nocturnal Hemoglobinuria (PNH) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04901936 | PNH | P2 | recruiting | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| NCT02264639 | APL-2 | P1 | completed | A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH |
PNH (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03531255 | — | P3 | completed | Pegcetacoplan Long Term Safety and Efficacy Extension Study |
| NCT03593200 | APL-2 | P2 | completed | A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH |
Acute Ischemic Stroke (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07495722 | SUCCESS | P1 | not yet recruiting | Safely Quenching Complement in Stroke Survivors |
Metastatic Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07214298 | — | P1/P2 | recruiting | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma |
Delayed Graft Function (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07020832 | DGF | P3 | recruiting | A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation |
Macular Degeneration, Age-related (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06722157 | VERDANT | P2 | active not recruiting | A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy |
Fallopian Tube Carcinosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04919629 | — | P2 | recruiting | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion |
Cold Agglutinin Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05096403 | CAD | P3 | completed | A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) |
Transplant-Associated Thrombotic Microangiopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05148299 | — | P2 | completed | A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation |
Amyotrophic Lateral Sclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04579666 | ALS | P2 | terminated | MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) |
Neovascular Age-related Macular Degeneration (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03465709 | APL-2 | P1/P2 | terminated | Pegcetacoplan (APL-2) in Neovascular AMD |
Neovascular Age-Related Macular Degeneration (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02461771 | ASAP II | P1 | completed | Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD |
Pegcetacoplan pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| DGF | NCT07020832 | P3 | recruiting | Delayed Graft Function | 320 | — |
| VALE | NCT05809531 | P3 | active not recruiting | C3G | 100 | — |
| GALE | NCT04770545 | P3 | completed | Geographic Atrophy Secondary to Age-related Macular Degeneration | 792 | — |
| VALIANT | NCT05067127 | P3 | completed | C3G | 124 | — |
| CAD | NCT05096403 | P3 | completed | Cold Agglutinin Disease | 24 | — |
| PNH | NCT03500549 | P3 | completed | Paroxysmal Nocturnal Hemoglobinuria | 80 | — |
| PNH | NCT04901936 | P2 | recruiting | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 12 | — |
| APL-2 | NCT07215390 | P2 | recruiting | Geographic Atrophy Secondary to Age-related Macular Degeneration | 240 | — |
| VERDANT | NCT06722157 | P2 | active not recruiting | Macular Degeneration, Age-related | 202 | — |
| NOBLE | NCT04572854 | P2 | completed | C3G | 13 | — |
| ALS | NCT04579666 | P2 | terminated | Amyotrophic Lateral Sclerosis | 249 | — |
| APL-2 | NCT03593200 | P2 | completed | PNH | 4 | — |
| FILLY | NCT02503332 | P2 | completed | Geographic Atrophy | 246 | — |
Terminated and withdrawn Pegcetacoplan trials (2)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04579666terminatedMERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
- NCT03465709terminatedPegcetacoplan (APL-2) in Neovascular AMD
All Pegcetacoplan trials (27)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05776472 | COMPLETE | A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | — | recruiting | 200 | Swedish Orphan Biovitrum | Jun 2023 |
| NCT04901936 | PNH | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | P2 | recruiting | 12 | Apellis Pharmaceuticals, Inc. | Feb 2021 |
| NCT07214298 | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | P1/P2 | recruiting | 35 | Roswell Park Cancer Institute | Feb 2026 | |
| NCT07020832 | DGF | A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation | P3 | recruiting | 320 | Apellis Pharmaceuticals, Inc. | Feb 2026 |
| NCT04919629 | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | P2 | recruiting | 60 | Roswell Park Cancer Institute | Apr 2023 | |
| NCT07215390 | APL-2 | A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio | P2 | recruiting | 240 | Apellis Pharmaceuticals, Inc. | Jun 2025 |
| NCT07495722 | SUCCESS | Safely Quenching Complement in Stroke Survivors | P1 | not yet recruiting | 20 | Columbia University | Oct 2026 |
| NCT05809531 | VALE | An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis | P3 | active not recruiting | 100 | Apellis Pharmaceuticals, Inc. | May 2023 |
| NCT06161584 | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | — | active not recruiting | 300 | Apellis Pharmaceuticals, Inc. | Sep 2023 | |
| NCT06722157 | VERDANT | A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | P2 | active not recruiting | 202 | Boehringer Ingelheim | Jan 2025 |
| NCT03531255 | Pegcetacoplan Long Term Safety and Efficacy Extension Study | P3 | completed | 137 | Apellis Pharmaceuticals, Inc. | Aug 2018 | |
| NCT04572854 | NOBLE | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN | P2 | completed | 13 | Apellis Pharmaceuticals, Inc. | Sep 2021 |
| NCT07214740 | Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe | P3 | completed | 44 | Apellis Pharmaceuticals, Inc. | Oct 2025 | |
| NCT04770545 | GALE | An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD | P3 | completed | 792 | Apellis Pharmaceuticals, Inc. | Mar 2021 |
| NCT05067127 | VALIANT | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis | P3 | completed | 124 | Apellis Pharmaceuticals, Inc. | Nov 2021 |
| NCT05148299 | A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation | P2 | completed | 12 | Swedish Orphan Biovitrum | Feb 2022 | |
| NCT05096403 | CAD | A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) | P3 | completed | 24 | Swedish Orphan Biovitrum | Oct 2022 |
| NCT04579666 | ALS | MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) | P2 | terminated | 249 | Apellis Pharmaceuticals, Inc. | Sep 2020 |
| NCT03777332 | Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy | P1 | completed | 19 | Apellis Pharmaceuticals, Inc. | Nov 2018 | |
| NCT04729062 | C3G/Primary IC-MPGN EAP | — | approved for marketing | 0 | Apellis Pharmaceuticals, Inc. | — | |
| NCT03500549 | PNH | Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | P3 | completed | 80 | Apellis Pharmaceuticals, Inc. | Jun 2018 |
| NCT03593200 | APL-2 | A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH | P2 | completed | 4 | Apellis Pharmaceuticals, Inc. | Aug 2018 |
| NCT02588833 | PADDOCK | Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects. | P1 | completed | 23 | Apellis Pharmaceuticals, Inc. | Dec 2015 |
| NCT03465709 | APL-2 | Pegcetacoplan (APL-2) in Neovascular AMD | P1/P2 | terminated | 17 | Apellis Pharmaceuticals, Inc. | Feb 2018 |
| NCT02264639 | APL-2 | A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH | P1 | completed | 9 | Apellis Pharmaceuticals, Inc. | Feb 2015 |
| NCT02503332 | FILLY | Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy | P2 | completed | 246 | Apellis Pharmaceuticals, Inc. | Sep 2015 |
| NCT02461771 | ASAP II | Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD | P1 | completed | 13 | Apellis Pharmaceuticals, Inc. | Jan 2015 |
Pegcetacoplan clinical trials: frequently asked questions
- How many Pegcetacoplan clinical trials are there?
- 27 Pegcetacoplan clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants. 14 are marked completed.
- Are Pegcetacoplan clinical trials recruiting in 2026?
- Yes — 6 Pegcetacoplan trials are actively recruiting in 2026, with 71 U.S. sites across 24 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Pegcetacoplan being studied for?
- Pegcetacoplan is being studied for Complement 3 Glomerulopathy (C3G), C3G, Geographic Atrophy, C3 Glomerulonephritis, Membranoproliferative Glomerulonephritis and 44 more. The trials are grouped by indication on this page.
- What phase is Pegcetacoplan in?
- Pegcetacoplan clinical trials span 8 Phase 3, 9 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Pegcetacoplan clinical trials?
- The lead sponsor across the most Pegcetacoplan trials is Apellis Pharmaceuticals, Inc., with 4 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Pegcetacoplanas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: